Zachary Spigelman, MD
Hematology & Oncology · Derry, NHNPI 1063470011
Payments from drug & device makers
What this record shows
7 manufacturers reported payments, led by Pfizer at 26.2% of the total. Reporting peaked in 2019 at $117 and has fallen 78.8% since, to $25 in 2025.
Across 11 payments — averaging $25.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$74
- Rigel Pharmaceuticals, Inc.$59
- Novartis$47
- Johnson & Johnson$44
- Sobi, Inc$25
- E.r. Squibb & Sons, L.L.C.$21
- plus $12 from 1 others
Across 2 payments — averaging $967.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$2K
What the payments were for
- Food & beverage$13146%
- Education$15154%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 4 | $74 |
| Rigel Pharmaceuticals, Inc. | 1 | $59 |
| Novartis | 1 | $47 |
| Johnson & Johnson | 2 | $44 |
| Sobi, Inc | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Gilead | 1 | $12 |
How this compares
$282 in reported general payments places this provider in the 55th percentile of 61 hematology & oncology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NexviazymeAvalglucosidase Alfa-Ngpt | 11 | $558,910 |
| CalquenceAcalabrutinib Maleate | 20 | $289,535 |
| EliquisApixaban | 34 | $39,600 |
| Atovaquone | 13 | $2,608 |
| Abiraterone Acetate | 12 | $1,578 |
| Fentanyl | 11 | $1,145 |
| Letrozole | 58 | $952 |
| Dexamethasone | 17 | $652 |
| Omeprazole | 35 | $630 |
| Nystatin | 20 | $534 |
| Megestrol Acetate | 11 | $517 |
| Lorazepam | 58 | $453 |
| Duloxetine Hcl | 18 | $398 |
| Anastrozole | 21 | $360 |
| Oxycodone Hcl | 30 | $318 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $74 | $39,60034 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 61 hematology & oncology providers in New Hampshire.
Other hematology & oncology in Derry
- Cocav RauwerdinkDerry$189
- Frederick LansiganLebanon$23K
- Parth ShahLebanon$18K
- Nancy ChunNashua$7K
- Amy BessnowDover$6K
- Konstantin DragnevLebanon$5K
- Keisuke ShiraiLebanon$5K
- Eric LubinerNorth Conway$3K
- David ReismanManchester$2K
- Ivy Riano MonsalveLebanon$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.